Invion Limited
Invion Limited
Your view on IVX.AX
Overview
What the company does, where it operates, and who runs it.
About Invion Limited
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Thian Chew
- Headquarters
- 385 Bourke Street, Melbourne, VIC, AU
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Thian Chew
- Headquarters
- 385 Bourke Street, Melbourne, VIC, AU
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types.
Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma.
The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments.
Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Invion Limited. Starting points for Invion Limited: EPS -AUD 0.06, beta 0.40 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Invion Limited. Invion Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Invion Limited. Trailing twelve-month EPS for Invion Limited stands at -AUD 0.06. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Invion Limited. Invion Limited has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACR.AXAcrux Limited | Healthcare | Biotechnology | — | ||
| ADR.AXAdherium Limited | Healthcare | Medical - Devices | — | ||
| BGT.AXBio-Gene Technology Limited | Basic Materials | Agricultural Inputs | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| CAN.AXCann Group Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| HIQ.AXHITIQ Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| ICR.AXIntelicare Holdings Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| UPCUniverse Pharmaceuticals Inc. | Healthcare | NASDAQ | $961,098 | ||
| USMJNorth American Cannabis Holdings, Inc. | Healthcare | OTC | $137,858 | ||
| VDRMViaDerma, Inc. | Healthcare | OTC | $493,484 | ||
| VENI.CNVencanna Ventures Inc. | Healthcare | CNQ | $1.1M | ||
| VEXT.CNVext Science, Inc. | Healthcare | CNQ | $59.5M | ||
| VEXTFVext Science, Inc. | Healthcare | OTC | $43.8M | ||
| VIBE.CNVibe Growth Corporation | Healthcare | CNQ | $647,819 | ||
| VIBEFVibe Growth Corporation | Healthcare | OTC | $431,880 | ||
| VIT.AXVitura Health Limited | Healthcare | ASX | — | ||
| VIVXFAvivagen Inc. | Healthcare | OTC | $7,769 | ||
| VLS.AXVita Life Sciences Limited | Healthcare | ASX | — | ||
| VM.VVoyageur Pharmaceuticals Ltd. | Healthcare | TSXV | $23.1M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Invion Limited.